ITP in the COVID19 Era
Immune Thrombocytopenia in the COVID-19 Era: A national, multi-centre audit
Immune Thrombocytopenia (ITP) in the COVID-19 Era seeks to assess any change in the management of ITP that has occurred as a consequence of the COVID-19 pandemic.
This national, multi-centre audit is being conducted by Dr Sue Pavord, Dr Ed Watson and Dr Alex Rampotas at Oxford University Hospitals NHS Foundation Trust. Recruitment closed in May 2021 after receiving over 340 submissions. Data analysis is now under way.
Contact: edmund.watson@ouh.nhs.uk
Read More
This audit was launched in June 2020. The COVID-19 pandemic has increased the risks associated with immunosuppressive therapies for ITP and therefore creates a difficult clinical dilemma when managing patients. The investigators are keen to hear about all episodes of new or relapsed/refractory ITP treated since March 2020, regardless of whether the patient contracted COVID-19 or not.
The audit closed to recruitment in May 2021, and data analysis of over 340 submissions is now underway.